Allogene Therapeutics Inc (NASDAQ:ALLO)’s 12-Month Price Target Currently Stands At 55
In last trading session, Allogene Therapeutics Inc (NASDAQ:ALLO) saw 3.13 million shares changing hands with its beta currently measuring 0.33. Company’s recent per share price